Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1

Current HIV Research

Volumn 6, Issue 4, 2008, Pages 306-317

  Norelli, Sandro ^a   El Daker, Sary ^a   D'Ostilio, Daniela ^a   Mele, Federico ^a   Mancini, Fabiola ^a   Taglia, Fabiana ^a   Ruggieri, Anna ^a   Ciccozzi, Massimo ^a   Cauda, Roberto ^b   Ciervo, Alessandra ^a   Barreca, Maria L ^c   Pistello, Mauro ^c   Bendinelli, Mauro ^d   Savarino, Andrea ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

Animal AIDS model; Feline immunodeficiency virus; Non peptide inhibitor; Protease; Retrovirus

Indexed keywords

ALANINE; AMPRENAVIR PHOSPHATE; ASPARAGINE; ASPARTIC ACID; ATAZANAVIR; DARUNAVIR; HYDROGEN; INDINAVIR; ISOLEUCINE; LEUCINE; LOPINAVIR; METHIONINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TIPRANAVIR; VALINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CAT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTALLOGRAPHY; DIMERIZATION; DISEASE MODEL; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; FELINE IMMUNODEFICIENCY VIRUS; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYDROGEN BOND; INHIBITION KINETICS; MOLECULAR DOCKING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PROTEIN INTERACTION; REVIEW; SEQUENCE ALIGNMENT; TREATMENT OUTCOME; VIRUS REPLICATION; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTI-HIV AGENTS; CATS; CELL LINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PYRIDINES; PYRONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 52449102379     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208785132527     Document Type: Review

References (58)

1. Pedersen NC, Ho EW, Brown ML, Yamamoto JK. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1997; 235: 790-3.
2. Sparger EE, Luciw PA, Elder JH, Yamamoto JK, Lowenstine LJ and Pedersen NC. (1989) Feline immunodeficiency virus is a lenti-virus associated with an AIDS-like disease in cats. AIDS 1989, 3(Suppl 1): S43-9.
3. Vahlenkamp TW, Tompkins MB, Tompkins WAF. FIV as a model for AIDS pathogenesis studies. In vivo models of HIV disease and control. In: Friedman H, Specter S, Bendinelli M. Springer Science+ Business Media. 2006; 239-73.
4. Hartmann K, Stengel C. FIV as a model for HIV treatment. In: In vivo models of HIV disease and control. Edited by Friedman H, Specter S, Bendinelli M. Springer Science+ Business Media. 2006, 333-364.
5. Bisset LR, Lutz H, Böni J, Hofmann-Lehmann R, Lüthy R, Shüpbach J. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Res 2002; 53: 35-45.
6. Auwerx J, Esnouf R, De Clercq E, Balzarini J. Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. Mol Pharmacol 2004; 65: 244-51.
7. Lin YC, Beck Z, Morris GM, Olson AJ, Elder JH. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J Virol 2003; 77: 6589-600.
8. Savarino A, Pistello M, D'Ostilio D, et al. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to re-design antiretroviral treatment for feline AIDS. Retrovirology 2007; 4: 79.
9. Laco G, Schalk-Hini C, Lubkowski J, et al. Crystal structures of the inactive D30N mutant of feline immunodeficiency virus protease complexed with a substrate and an inhibitor. Biochemistry 1997; 36: 10696-708.
10. Wlondawer A, Gustchina A, Reshetnikova L, et al. Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Biol 1995; 2: 480-8.
11. Schnölzer M, Rackwitz HR, Gustchina A, et al. Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. Virology 1996; 224: 268-75.
12. Tacconelli E, Savarino A, De Bernardis F, Cauda R, Cassone A. Candidiasis and HIV-protease inhibitors: the expected and the unexpected. Curr Med Chem Immunol Endocr Metab Agents 2004; 4(l), pp. 49-59.
13. Savarino A. Expanding the frontiers of existing antiviral drugs: possible effects of HIV-1 protease inhibitors against SARS and avian influenza. J Clin Virol 2005; 34: 170-8.
14. Slee DH, Laslo KL, Elder JH, et al. Selectivity in the inhibition of HIV and FIV protease: inhibitory and mechanistic studies of pyrrolidine-containing alpha-keto amide and hydroxyethylamine core structures. J Am Chem Soc 1995; 117: 11867-78.
15. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother 2006; 50: 639-48.
16. Schmidtke G, Holzhütter HG, Bogyo M, et al. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999; 274: 35734-40.
17. Savarino A, Lucia MB, Rastrelli E, et al. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 2004; 35: 223-32.
18. Lucia MB, Golotta C, Rutella S, Rastrelli E, Savarino A, Cauda R. Atazanavir inhibits P-glycoprotein and multidrug resistance-associated protein efflux activity. J Acquir Immune Defic Syndr 2005; 39: 635-347.
19. Li M, Morris GM, Lee T, et al. Structural studies of FIV and HIV-1 proteases complexed with an efficient inhibitor of FIV protease. Proteins 2000; 38: 29-40.
20. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997; 5: 129-42.
21. Lee T, Laco GS, Torbett BE, et al. Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc Natl Acad Sci USA 1998; 95: 939-44.
22. Huitron-Resendiz S, de Rozièeres S, sanchez-Alavez M, et al. Resolution and prevention of feline immunodeficiency virus-induced neurological deficits by treatment with the protease inhibitor TL-3. J Virol 2004; 78: 4525-32.
23. De Rozières S, Swan CH, Sheeter DA, et al. Assessment of FIV-C infection of cats as a function of treatment with the protease inhibitor, TL-3. Retrovirology 2004; 1: 38.
24. Kaplan SS, Hicks CB. Safety and antiviral activity of lopinavir/ ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection. J Antimicrob Chemother 2005; 56: 273-6.
25. Mastrolorenzo A, Ruscom S, Scozzafava A, Barbaro G, Supuran CT. Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors. Curr Med Chem 2007; 14: 2734-48.
26. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS:232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47: 1324-33.
27. Muzammil S, Armstrong AA, Kang LW, et al. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations. J Virol 2007; 81: 5144-54.
28. U.S. National Center for Biotechnology Homepage: [http://www.ncbi.nlm.nih.gov] Accessed June 11, 2008.
29. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997; 25: 4876-82.
30. Hall TA. Bioedit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp 1999; 41: 95-98.
31. Kaplan W, Littlejohn TG. Swiss-PDB Viewer (Deep View). Brief Bioinform 2001; 2:195-7.
32. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24: 1596-9.
33. Matteucci D, Mazzetti P, Baldinotti F, Zaccaro L, Bendinelli M. The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation. Vet Immunol Immunopathol 1995; 46: 71-82.
34. Yamamoto JK, Ackley CD, Zochlinski H, et al. Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology 1991; 32: 361-75.
35. Lombardi S, Massi C, Indino E, et al. Inhibition of feline immunodeficiency virus infection in vitro by envelope glycoprotein synthetic peptides. Virology 1996; 220: 274-84.
36. Savarino A, Calosso L, Piragino A, et al. Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type-1. Cell Biochem Funct 1999; 17: 47-55.
37. Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS 2001; 15: 2221-9.
38. Lombardi S, Poli A, Massi C, et al. Detection of feline immunode-ficiency virus p24 antigen and p24-specific antibodies by monoclonal antibody-based assays. J Virol Methods 1994; 46: 287-301.
39. VEGA ZZ homepage [http://www.ddl.unimi.it/vega/index2.htm] Accessed June 11, 2008.
40. Trylska J, Grochowski P, McCammon JA. The role of hydrogen bonding in the enzymatic reaction catalyzed by HIV-1 protease. Protein Sci 2004; 13: 513-28.
41. Mercury [http://www.ccdc.cam.ac.uk/products/mercury] Accessed June 11, 2008.
42. Jones G, Willet P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-48.
43. Nissink JWM, Verdonk ML, Klebe G. Simple knowledge-based descriptors to predict protein-ligand interactions. methodology and validation. J Comput Aided Mol Des 2000; 14: 787-803.
44. Jorgensen WL, Maxwell DS, Tirado-Rives J. Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 1996; 118: 11225-36.
45. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions. Prot Eng 1995; 8: 127-34.
46. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003; 31: 298-303.
47. Perno CF, Newcomb FM, Davis DA, et al. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis 1998; 178: 413-22.
48. Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. J Acquired Immune Deficiency Syndromes 2003; 34(Suppl 1): S91-4.
49. Mo H, Parkin N, Stewart KD, et al. Identification and structural characterization of 184C and 184A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication. Antimicrob Agents Chemother 2007; 51: 732-5.
50. Foulkes JE, Prabu-Jeyabalan M, Cooper D, et al. Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. J Virol 2006; 80: 6906-16.
51. Savarino A, Lucia MB, ter Heine R, et al. Quinoline antimalarials as investigational drugs for HIV-1/AIDS: In vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. Drug Dev Res 2006; 67: 806-817.
52. Gong RJ, Eggers B, Yong H, Gali V, et al. Atazanavir susceptibility spectrum extends to HIV-1 non-B subtypes and HIV-2 viral isolates. 15th International HIV Drug Resistance Workshop. Antivir Ther 2006; 11: S100. Abstract no 90.
53. Koh Y, Matsumi S, Das D, Amano M, et al. Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. J Biol Chem 2007; 282: 28709-20.
54. Dias AS, Bester MJ, Britz RF, Apostolides Z. Animal models used for the evaluation of antiretroviral therapies. Curr HIV Res 2004; 4: 431-46.
55. Wildman DE, Uddin M, Opazo JC, et al. Genomics, biogeography, and the diversification of placental mammals. Proc Natl Acad Sci USA 2007; 104: 14395-400
56. Prasad AB, Allard MW. Confirming the phylogeny of mammals by use of large comparative sequence dataset. Mol Biol Evol 2008; [Epub ahead of print].
57. Adkison KK, Shachoy-Clark A, Fang L, et al. The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects. Br J Clin Pharmacol 2006; 62: 336-44.
58. Warren L. DeLano "The PyMOL Molecular Graphics System." DeLano Scientific LLC, San Carlos, CA, USA. [http://www.pymol.org] Accessed June 11, 2008.